MX2018003351A - Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. - Google Patents
Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer.Info
- Publication number
- MX2018003351A MX2018003351A MX2018003351A MX2018003351A MX2018003351A MX 2018003351 A MX2018003351 A MX 2018003351A MX 2018003351 A MX2018003351 A MX 2018003351A MX 2018003351 A MX2018003351 A MX 2018003351A MX 2018003351 A MX2018003351 A MX 2018003351A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- compounds
- btk inhibitors
- pyrazolopyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
La presente invención se refiere a compuestos novedosos. Los compuestos de la invención sin inhibidores de tirosina quinasa. Específicamente, los compuestos de la invención son útiles como inhibidores de la tirosina quinasa de Bruton (BTK). La invención también contempla el uso de los compuestos para tratar las condiciones tratables por la inhibición de la tirosina quinasa de Bruton, por ejemplo, cáncer, linfoma, leucemia y enfermedades inmunológicas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1516445.2A GB201516445D0 (en) | 2015-09-16 | 2015-09-16 | Compounds |
GBGB1522246.6A GB201522246D0 (en) | 2015-12-16 | 2015-12-16 | Compounds |
GBGB1613947.9A GB201613947D0 (en) | 2016-08-15 | 2016-08-15 | Compounds |
PCT/GB2016/052897 WO2017046604A1 (en) | 2015-09-16 | 2016-09-16 | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018003351A true MX2018003351A (es) | 2018-09-17 |
Family
ID=56985638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018003351A MX2018003351A (es) | 2015-09-16 | 2016-09-16 | Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. |
Country Status (15)
Country | Link |
---|---|
US (3) | US10611766B2 (es) |
EP (2) | EP3350184B1 (es) |
JP (2) | JP7337502B2 (es) |
KR (1) | KR20180109842A (es) |
CN (2) | CN108431007B (es) |
AU (1) | AU2016322063A1 (es) |
CA (1) | CA2998796A1 (es) |
CL (1) | CL2018000706A1 (es) |
EA (1) | EA201890730A1 (es) |
ES (1) | ES2929528T3 (es) |
HK (1) | HK1258779A1 (es) |
IL (1) | IL258154A (es) |
MX (1) | MX2018003351A (es) |
PH (1) | PH12018500587A1 (es) |
WO (1) | WO2017046604A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
EA201890730A1 (ru) | 2015-09-16 | 2018-10-31 | Локсо Онколоджи, Инк. | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования |
SG10202012498TA (en) | 2015-12-16 | 2021-01-28 | Loxo Oncology Inc | Compounds useful as kinase inhibitors |
WO2019222509A1 (en) * | 2018-05-16 | 2019-11-21 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidines as mertk inhibitors and their application in cancer treatment |
CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
CA3126940A1 (en) * | 2019-01-18 | 2020-07-23 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药(上海)有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20230145305A1 (en) * | 2020-03-12 | 2023-05-11 | Fochon Biosciences, Ltd. | Compounds useful as kinase inhibitors |
CN114075190A (zh) * | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
CN114573586B (zh) * | 2020-11-28 | 2023-11-03 | 杭州和正医药有限公司 | 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
EP4039688A3 (en) * | 2021-02-03 | 2022-11-23 | Accutar Biotechnology Inc. | Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
WO2023165570A1 (zh) * | 2022-03-03 | 2023-09-07 | 深圳市塔吉瑞生物医药有限公司 | 环烷基或杂环基取代的杂芳基化合物及其组合物及用途 |
CN115304607B (zh) * | 2022-07-06 | 2023-06-27 | 华南农业大学 | 吡唑并嘧啶衍生物的制备方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
CN1390219A (zh) | 1999-09-17 | 2003-01-08 | 艾博特股份有限两合公司 | 作为治疗剂的吡唑并嘧啶类 |
WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
WO2008005457A2 (en) | 2006-06-30 | 2008-01-10 | Sunesis Pharmaceuticals | Pyridinonyl pdk1 inhibitors |
SI2526934T1 (sl) | 2006-09-22 | 2016-04-29 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
WO2008054827A2 (en) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
EP2561875A3 (en) | 2007-03-28 | 2013-06-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
CN102105459B (zh) | 2008-07-24 | 2014-09-10 | 内尔维阿诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑类 |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
US9580427B2 (en) | 2011-05-17 | 2017-02-28 | The Regents Of The University Of California | Kinase inhibitors |
US8962831B2 (en) | 2011-05-17 | 2015-02-24 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
BR112014000653A2 (pt) | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
MX368112B (es) | 2012-06-18 | 2019-09-18 | Principia Biopharma Inc | Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias. |
CA2782774A1 (en) | 2012-07-06 | 2014-01-06 | Pharmascience Inc. | Protein kinase inhibitors |
US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
CA2888960C (en) | 2012-11-02 | 2017-08-15 | Pfizer Inc. | Bruton's tyrosine kinase inhibitors |
PE20151495A1 (es) * | 2012-11-15 | 2015-10-23 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas |
CN103848810A (zh) | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
GB201309085D0 (en) * | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
JP6615752B2 (ja) | 2013-09-30 | 2019-12-04 | グアンジョウ・イノケア・ファーマ・テク・カンパニー・リミテッド | Btkの置換ニコチンイミド阻害剤およびそれらの調製、ならびにがん、炎症および自己免疫疾患の治療における使用 |
EP3082809B1 (en) | 2013-12-20 | 2021-01-20 | Merck Sharp & Dohme Corp. | Btk inhibitors |
BR112016018948B1 (pt) | 2014-02-21 | 2023-01-17 | Principia Biopharma Inc | Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso |
GB201404987D0 (en) | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
CN105085474B (zh) | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) * | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
EA201890730A1 (ru) | 2015-09-16 | 2018-10-31 | Локсо Онколоджи, Инк. | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования |
SG10202012498TA (en) | 2015-12-16 | 2021-01-28 | Loxo Oncology Inc | Compounds useful as kinase inhibitors |
-
2016
- 2016-09-16 EA EA201890730A patent/EA201890730A1/ru unknown
- 2016-09-16 EP EP16770328.9A patent/EP3350184B1/en active Active
- 2016-09-16 US US15/762,367 patent/US10611766B2/en active Active
- 2016-09-16 CN CN201680066694.6A patent/CN108431007B/zh active Active
- 2016-09-16 AU AU2016322063A patent/AU2016322063A1/en not_active Abandoned
- 2016-09-16 EP EP22189973.5A patent/EP4116303A1/en active Pending
- 2016-09-16 MX MX2018003351A patent/MX2018003351A/es unknown
- 2016-09-16 KR KR1020187010521A patent/KR20180109842A/ko unknown
- 2016-09-16 ES ES16770328T patent/ES2929528T3/es active Active
- 2016-09-16 CN CN202210413117.7A patent/CN114685516A/zh active Pending
- 2016-09-16 CA CA2998796A patent/CA2998796A1/en active Pending
- 2016-09-16 JP JP2018514423A patent/JP7337502B2/ja active Active
- 2016-09-16 WO PCT/GB2016/052897 patent/WO2017046604A1/en active Application Filing
-
2018
- 2018-03-15 IL IL258154A patent/IL258154A/en unknown
- 2018-03-16 PH PH12018500587A patent/PH12018500587A1/en unknown
- 2018-03-16 CL CL2018000706A patent/CL2018000706A1/es unknown
- 2018-08-22 US US16/109,223 patent/US10399989B2/en active Active
- 2018-08-27 US US16/113,533 patent/US10399990B2/en not_active Expired - Fee Related
-
2019
- 2019-01-23 HK HK19101139.9A patent/HK1258779A1/zh unknown
-
2023
- 2023-06-13 JP JP2023097033A patent/JP2023134428A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023134428A (ja) | 2023-09-27 |
ES2929528T3 (es) | 2022-11-29 |
JP7337502B2 (ja) | 2023-09-04 |
KR20180109842A (ko) | 2018-10-08 |
CA2998796A1 (en) | 2017-03-23 |
CL2018000706A1 (es) | 2018-07-13 |
US10611766B2 (en) | 2020-04-07 |
US20180362537A1 (en) | 2018-12-20 |
HK1258779A1 (zh) | 2019-11-22 |
EP3350184B1 (en) | 2022-10-19 |
CN114685516A (zh) | 2022-07-01 |
WO2017046604A1 (en) | 2017-03-23 |
US10399990B2 (en) | 2019-09-03 |
EP4116303A1 (en) | 2023-01-11 |
US20180298008A1 (en) | 2018-10-18 |
PH12018500587A1 (en) | 2018-10-15 |
CN108431007B (zh) | 2022-06-07 |
IL258154A (en) | 2018-05-31 |
JP2018527384A (ja) | 2018-09-20 |
EP3350184A1 (en) | 2018-07-25 |
EA201890730A1 (ru) | 2018-10-31 |
CN108431007A (zh) | 2018-08-21 |
US10399989B2 (en) | 2019-09-03 |
AU2016322063A1 (en) | 2018-04-12 |
US20180362533A1 (en) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
PH12015502028A1 (en) | Ido inhibitors | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
MX2019000542A (es) | Derivados de pirazolilaminobenzimidazol como inhibidores de jak. | |
MX2021011699A (es) | Derivados de quinolina y su uso para el tratamiento del cancer. | |
EA201992557A1 (ru) | Противоопухолевые соединения | |
MY192305A (en) | Bipyrazole derivatives as jak inhibitors |